Ilmarinen Mutual Pension Insurance Co Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Ilmarinen Mutual Pension Insurance Co lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 40.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 12,500 shares of the biopharmaceutical company’s stock after selling 8,500 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Alnylam Pharmaceuticals were worth $4,971,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Mediolanum International Funds Ltd purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $11,389,000. iA Global Asset Management Inc. raised its holdings in Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after acquiring an additional 16,133 shares during the last quarter. Perpetual Ltd purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $2,004,000. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after acquiring an additional 268,313 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in Alnylam Pharmaceuticals by 24.2% in the 3rd quarter. Envestnet Asset Management Inc. now owns 118,964 shares of the biopharmaceutical company’s stock worth $54,248,000 after acquiring an additional 23,168 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $301.98 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $284.28 and a 52 week high of $495.55. The firm has a market capitalization of $40.32 billion, a P/E ratio of 82.51 and a beta of 0.31. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The company has a 50-day moving average price of $309.38 and a 200-day moving average price of $354.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the firm earned ($0.44) EPS. The business’s revenue for the quarter was up 96.4% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ALNY shares. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Truist Financial decreased their target price on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Finally, Freedom Capital raised Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $463.13.

Insider Activity

In other news, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This represents a 19.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Yvonne Greenstreet sold 6,799 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the sale, the chief executive officer owned 98,628 shares of the company’s stock, valued at $32,315,464.20. This trade represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 21,255 shares of company stock worth $6,930,337. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.